Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 1
1996 3
1997 3
1998 2
1999 2
2000 1
2002 2
2003 3
2004 3
2005 1
2006 1
2007 1
2008 5
2009 6
2010 6
2011 5
2012 4
2013 4
2014 6
2015 5
2016 2
2017 4
2018 6
2019 3
2020 10
2021 6
2022 7
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, Fenioux C, Devos P, Gougis P, Dres M, Demoule A, Psimaras D, Lenglet T, Maisonobe T, De Chambrun MP, Hekimian G, Straus C, Gonzalez-Bermejo J, Klatzmann D, Rigolet A, Guillaume-Jugnot P, Champtiaux N, Benveniste O, Weiss N, Saheb S, Rouvier P, Plu I, Gandjbakhch E, Kerneis M, Hammoudi N, Zahr N, Llontop C, Morelot-Panzini C, Lehmann L, Qin J, Moslehi JJ, Rosenzwajg M, Similowski T, Allenbach Y. Salem JE, et al. Among authors: rosenzwajg m. Cancer Discov. 2023 May 4;13(5):1100-1115. doi: 10.1158/2159-8290.CD-22-1180. Cancer Discov. 2023. PMID: 36815259
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J; International ICI-Myocarditis Registry; Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE. Fenioux C, et al. Among authors: rosenzwajg m. Nat Med. 2023 Dec;29(12):3100-3110. doi: 10.1038/s41591-023-02591-2. Epub 2023 Oct 26. Nat Med. 2023. PMID: 37884625
Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.
Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, Bourrier A, Le Gall G, Lalande V, De Rougemont A, Kirchgesner J, Daguenel A, Cachanado M, Rousseau A, Drouet É, Rosenzwajg M, Hagege H, Dray X, Klatzman D, Marteau P; Saint-Antoine IBD Network; Beaugerie L, Simon T. Sokol H, et al. Among authors: rosenzwajg m. Microbiome. 2020 Feb 3;8(1):12. doi: 10.1186/s40168-020-0792-5. Microbiome. 2020. PMID: 32014035 Free PMC article. Clinical Trial.
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, Leroux D, Vazquez T, Riemekasten G, Smolen JS, Tsokos G, Klatzmann D. Humrich JY, et al. Among authors: rosenzwajg m. Ann Rheum Dis. 2022 Dec;81(12):1685-1694. doi: 10.1136/ard-2022-222501. Epub 2022 Aug 16. Ann Rheum Dis. 2022. PMID: 35973803 Clinical Trial.
CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis.
Régnier P, Le Joncour A, Maciejewski-Duval A, Darrasse-Jèze G, Dolladille C, Meijers WC, Bastarache L, Fouret P, Bruneval P, Arbaretaz F, Sayetta C, Márquez A, Rosenzwajg M, Klatzmann D, Cacoub P, Moslehi JJ, Salem JE, Saadoun D. Régnier P, et al. Among authors: rosenzwajg m. Circ Res. 2023 Aug 4;133(4):298-312. doi: 10.1161/CIRCRESAHA.122.322330. Epub 2023 Jul 12. Circ Res. 2023. PMID: 37435729 Free article.
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
Louapre C, Rosenzwajg M, Golse M, Roux A, Pitoiset F, Adda L, Tchitchek N, Papeix C, Maillart E, Ungureanu A, Charbonnier-Beaupel F, Galanaud D, Corvol JC, Vicaut E, Lubetzki C, Klatzmann D. Louapre C, et al. Among authors: rosenzwajg m. J Neurol. 2023 Sep;270(9):4403-4414. doi: 10.1007/s00415-023-11690-6. Epub 2023 May 28. J Neurol. 2023. PMID: 37245191 Clinical Trial.
Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J; International ICI-Myocarditis Registry; Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE. Fenioux C, et al. Among authors: rosenzwajg m. Nat Med. 2023 Dec;29(12):3268. doi: 10.1038/s41591-023-02690-0. Nat Med. 2023. PMID: 38012317 No abstract available.
Targeting JAK/STAT pathway in Takayasu's arteritis.
Régnier P, Le Joncour A, Maciejewski-Duval A, Desbois AC, Comarmond C, Rosenzwajg M, Klatzmann D, Cacoub P, Saadoun D. Régnier P, et al. Among authors: rosenzwajg m. Ann Rheum Dis. 2020 Jul;79(7):951-959. doi: 10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25. Ann Rheum Dis. 2020. PMID: 32213496
107 results